JP2007526318A5

JP2007526318A5 -

Info

Publication number: JP2007526318A5
Application number: JP2007501899A
Authority: JP
Filing date: 2005-03-02
Publication date: 2008-04-03

Claims

A polypeptide for use as a self-transporter antigen, the polypeptide comprising:
(A) an amino acid sequence selected from the group consisting of SEQ ID NO: 54, SEQ ID NO: 6, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 78, and SEQ ID NO: 79;
(B) an amino acid sequence having at least 50% sequence identity to the amino acid sequence of (a); or (c) one or more fragments of at least 7 consecutive amino acids from the amino acid sequence of (a) or these A polypeptide comprising an amino acid sequence comprising a combination of:

2. The polypeptide according to claim 1, wherein the use is as an antigen to elicit a Chlamydia pneumoniae specific immune response.

3. The polypeptide of claim 2, wherein the use is for raising a systemic immune response in an individual infected with Chlamydia pneumoniae.

The polypeptide according to any one of claims 1 to 3, which is secreted into the cytoplasm of a host cell through a mechanism of a V-type autotransporter secretion system.

The polypeptide is selected from the group consisting of SEQ ID NO: 54, SEQ ID NO: 6, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 78 and SEQ ID NO: 79, and G, DG, VG, G, AV, G, IVG The polypeptide of any one of claims 1 to 3, which shares one or more common N-terminal sequence motifs selected from the group consisting of GTLGG, S, IVG, and M.

6. The polypeptide of claim 5, wherein the common N-terminal sequence motif is selected from the group consisting of GTLGG, S, IVG and M.

4. A polypeptide according to any one of claims 1 to 3 for use in diagnosis.

Use of the polypeptide according to any one of claims 1 to 3 in the preparation of a medicament for the prevention or treatment of Chlamydia pneumoniae infection in an individual.

9. Use according to claim 8, wherein the use uses a self-transporter protein that immunoreacts with seropositive sera of individuals infected with Chlamydia pneumoniae.

Use of a polypeptide according to any one of claims 1 to 3 in the preparation of an assay for the diagnosis of Chlamydia pneumoniae infection in an individual.

A composition for eliciting an immune response in an individual, hereinafter:
(A) an amino acid sequence selected from the group consisting of SEQ ID NO: 54, SEQ ID NO: 6, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 78, and SEQ ID NO: 79;
(B) an amino acid sequence having at least 50% sequence identity to the amino acid sequence of (a), or (c) at least 1, 2, 3, 4, 5, 6 or 7 from the amino acid sequence of (a) comprising one or more fragments or mixtures of these pieces of amino acids, polypeptides comprising the amino acid sequence, composition.

A composition for diagnosing an immune response in an individual, the composition comprising a binding agent that binds to a polypeptide according to any one of claims 1-3, wherein the composition, Contacted with a biological sample obtained from the individual, the amount of polypeptide binding to the binding agent is detected, and the amount of the polypeptide is predetermined to determine the presence of an immune response in the individual A composition that is compared to a cutoff value of .

13. A composition according to claim 11 or claim 12, wherein the polypeptide is described in any one of claims 1-3.

The method according to claim 11 or the use according to any one of claims 8 to 9, wherein the polypeptide is described in any one of claims 2-6.

A composition for raising an immune response, comprising one or more Chlamydia pneumoniae self-transporter proteins or immunogenic fragments thereof and one or more immunostimulants.

16. The composition of claim 15, wherein the Chlamydia pneumoniae self-transporter protein or immunogenic fragment thereof is:
(A) an amino acid sequence selected from the group consisting of SEQ ID NO: 54, SEQ ID NO: 6, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 78, SEQ ID NO: 86, and SEQ ID NO: 79;
(B) an amino acid sequence having at least 50% sequence identity to the amino acid sequence of (a); or (c) at least 1, 2, 3, 4, 5, 6 or 7 from the amino acid sequence of (a) A composition comprising an amino acid sequence comprising one or more fragments of amino acids or combinations thereof.

17. A composition according to claim 15 or 16, wherein the protein or immunogenic fragment thereof is described in any one of claims 1-3.

A composition for raising an immune response in a subject, comprising two or more Chlamydia pneumoniae autotransporter proteins or immunogenic fragments thereof.

19. The composition of claim 18, wherein the Chlamydia pneumoniae self-transporter protein or immunogenic fragment thereof is:
(A) an amino acid sequence selected from the group consisting of SEQ ID NO: 54, SEQ ID NO: 6, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 78, SEQ ID NO: 86, and SEQ ID NO: 79;
(B) an amino acid sequence having at least 50% sequence identity to the amino acid sequence of (a); or (c) at least 1, 2, 3, 4, 5, 6 or 7 from the amino acid sequence of (a) A composition comprising an amino acid sequence comprising one or more fragments of amino acids or combinations thereof.

20. The composition of claim 18 or 19, wherein the composition further comprises one or more immunostimulants.

17. A method of making a composition according to any one of claims 15 or 16, wherein the method comprises one or more Chlamydia pneumoniae self-transporter proteins or immunogenic fragments thereof and one or more immunostimulatory agents. A method comprising the step of mixing with.

20. A method of making a composition according to claim 18 or 19, wherein the method comprises mixing two or more Chlyamidia pneumoniae autotransporter proteins or immunogenic fragments thereof.

23. The method of claim 22, wherein the method comprises adding one or more immunostimulants to the Chlamydia pneumoniae autotransporter protein or immunogenic fragment.

A Chlamydia pneumoniae self-transporter protein selected from the group consisting of Cpn0794, Cpn0779, Cpn0796, Cpn0797, CPn0798 and Cpn0799, or an immunogenic fragment thereof, wherein the amino acid motif of the self-transporter protein is IVG, A, LGG And a protein comprising S.

25. The self-transporter protein of claim 24, wherein the repeated amino acid motif comprises IVG, A, LGG and S.

A polypeptide for use as a self-transporter antigen, said polypeptide comprising an amino acid sequence corresponding to SEQ ID NO: 86, an amino acid sequence having at least 50% sequence identity to SEQ ID NO: 86, or a sequence A polypeptide comprising an amino acid sequence comprising one or more fragments of at least 7 consecutive amino acids of number 86.

27. The polypeptide of claim 26, wherein the use is as an antigen to elicit a Chlamydia pneumoniae specific immune response.

The polypeptide according to claim 2, wherein the use is for raising a systemic immune response in an individual infected with Chlamydia pneumoniae.

29. Use of a polypeptide according to any one of claims 26 to 28 in the preparation of a medicament for the prevention or treatment of Chlamydia pneumoniae infection in an individual.

A composition for eliciting an immune response in an individual, SEQ ID NO 86 in the amino acid sequence corresponding an amino acid sequence having at least 50% sequence identity to SEQ ID NO: 86, or at least the SEQ ID NO: 86 polypeptides comprising an amino acid sequence comprising seven one or more fragments of consecutive amino acids, the composition.

A composition for diagnosing an immune response in an individual, the composition comprising a binding agent that binds to a polypeptide according to any one of claims 26 to 28, wherein the composition, The amount of polypeptide that is contacted with the biological sample obtained from the individual and that binds to the binding agent is detected in the biological sample , and the amount of polypeptide is a measure of the immune response in the individual. to determine the presence, Ru is compared with a predetermined cutoff value, composition.